Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Oct 15;93(21):11349–11353. doi: 10.1073/pnas.93.21.11349

Applications of pox virus vectors to vaccination: an update.

E Paoletti
PMCID: PMC38060  PMID: 8876138

Abstract

Recombinant pox viruses have been generated for vaccination against heterologous pathogens. Amongst these, the following are notable examples. (i) The engineering of the Copenhagen strain of vaccinia virus to express the rabies virus glycoprotein. When applied in baits, this recombinant has been shown to vaccinate the red fox in Europe and raccoons in the United States, stemming the spread of rabies virus infection in the wild. (ii) A fowlpox-based recombinant expressing the Newcastle disease virus fusion and hemagglutinin glycoproteins has been shown to protect commercial broiler chickens for their lifetime when the vaccine was administered at 1 day of age, even in the presence of maternal immunity against either the Newcastle disease virus or the pox vector. (iii) Recombinants of canarypox virus, which is restricted for replication to avian species, have provided protection against rabies virus challenge in cats and dogs, against canine distemper virus, feline leukemia virus, and equine influenza virus disease. In humans, canarypox virus-based recombinants expressing antigens from rabies virus, Japanese encephalitis virus, and HIV have been shown to be safe and immunogenic. (iv) A highly attenuated vaccinia derivative, NYVAC, has been engineered to express antigens from both animal and human pathogens. Safety and immunogenicity of NYVAC-based recombinants expressing the rabies virus glycoprotein, a polyprotein from Japanese encephalitis virus, and seven antigens from Plasmodium falciparum have been demonstrated to be safe and immunogenic in early human vaccine studies.

Full text

PDF
11350

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abimiku A. G., Franchini G., Tartaglia J., Aldrich K., Myagkikh M., Markham P. D., Chong P., Klein M., Kieny M. P., Paoletti E. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med. 1995 Apr;1(4):321–329. doi: 10.1038/nm0495-321. [DOI] [PubMed] [Google Scholar]
  2. Brockmeier S. L., Lager K. M., Tartaglia J., Riviere M., Paoletti E., Mengeling W. L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol. 1993 Dec;38(1-2):41–58. doi: 10.1016/0378-1135(93)90074-h. [DOI] [PubMed] [Google Scholar]
  3. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992 Jun 13;339(8807):1429–1432. doi: 10.1016/0140-6736(92)92027-d. [DOI] [PubMed] [Google Scholar]
  4. Cox W. I., Tartaglia J., Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology. 1993 Aug;195(2):845–850. doi: 10.1006/viro.1993.1442. [DOI] [PubMed] [Google Scholar]
  5. Egan M. A., Pavlat W. A., Tartaglia J., Paoletti E., Weinhold K. J., Clements M. L., Siliciano R. F. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis. 1995 Jun;171(6):1623–1627. doi: 10.1093/infdis/171.6.1623. [DOI] [PubMed] [Google Scholar]
  6. Franchini G., Robert-Guroff M., Tartaglia J., Aggarwal A., Abimiku A., Benson J., Markham P., Limbach K., Hurteau G., Fullen J. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res Hum Retroviruses. 1995 Aug;11(8):909–920. doi: 10.1089/aid.1995.11.909. [DOI] [PubMed] [Google Scholar]
  7. Franchini G., Tartaglia J., Markham P., Benson J., Fullen J., Wills M., Arp J., Dekaban G., Paoletti E., Gallo R. C. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. AIDS Res Hum Retroviruses. 1995 Feb;11(2):307–313. doi: 10.1089/aid.1995.11.307. [DOI] [PubMed] [Google Scholar]
  8. Fries L. F., Tartaglia J., Taylor J., Kauffman E. K., Meignier B., Paoletti E., Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 1996 Apr;14(5):428–434. doi: 10.1016/0264-410x(95)00171-v. [DOI] [PubMed] [Google Scholar]
  9. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 1990 Nov;179(1):247-66, 517-63. doi: 10.1016/0042-6822(90)90294-2. [DOI] [PubMed] [Google Scholar]
  10. Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst. 1992 Jul 15;84(14):1084–1091. doi: 10.1093/jnci/84.14.1084. [DOI] [PubMed] [Google Scholar]
  11. Kantor J., Irvine K., Abrams S., Snoy P., Olsen R., Greiner J., Kaufman H., Eggensperger D., Schlom J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 1992 Dec 15;52(24):6917–6925. [PubMed] [Google Scholar]
  12. Kieny M. P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J. P. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984 Nov 8;312(5990):163–166. doi: 10.1038/312163a0. [DOI] [PubMed] [Google Scholar]
  13. Konishi E., Pincus S., Paoletti E., Laegreid W. W., Shope R. E., Mason P. W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 1992 Sep;190(1):454–458. doi: 10.1016/0042-6822(92)91233-k. [DOI] [PubMed] [Google Scholar]
  14. Lanar D. E., Tine J. A., de Taisne C., Seguin M. C., Cox W. I., Winslow J. P., Ware L. A., Kauffman E. B., Gordon D., Ballou W. R. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun. 1996 May;64(5):1666–1671. doi: 10.1128/iai.64.5.1666-1671.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mackett M., Smith G. L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7415–7419. doi: 10.1073/pnas.79.23.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Myagkikh M., Alipanah S., Markham P. D., Tartaglia J., Paoletti E., Gallo R. C., Franchini G., Robert-Guroff M. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):985–992. doi: 10.1089/aid.1996.12.985. [DOI] [PubMed] [Google Scholar]
  17. Panicali D., Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927–4931. doi: 10.1073/pnas.79.16.4927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Perkus M. E., Tartaglia J., Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol. 1995 Jul;58(1):1–13. doi: 10.1002/jlb.58.1.1. [DOI] [PubMed] [Google Scholar]
  19. Pialoux G., Excler J. L., Rivière Y., Gonzalez-Canali G., Feuillie V., Coulaud P., Gluckman J. C., Matthews T. J., Meignier B., Kieny M. P. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses. 1995 Mar;11(3):373–381. doi: 10.1089/aid.1995.11.373. [DOI] [PubMed] [Google Scholar]
  20. Roth J., Dittmer D., Rea D., Tartaglia J., Paoletti E., Levine A. J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4781–4786. doi: 10.1073/pnas.93.10.4781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tartaglia J., Jarrett O., Neil J. C., Desmettre P., Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol. 1993 Apr;67(4):2370–2375. doi: 10.1128/jvi.67.4.2370-2375.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tartaglia J., Perkus M. E., Taylor J., Norton E. K., Audonnet J. C., Cox W. I., Davis S. W., van der Hoeven J., Meignier B., Riviere M. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992 May;188(1):217–232. doi: 10.1016/0042-6822(92)90752-b. [DOI] [PubMed] [Google Scholar]
  23. Taylor J., Christensen L., Gettig R., Goebel J., Bouquet J. F., Mickle T. R., Paoletti E. Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. Avian Dis. 1996 Jan-Mar;40(1):173–180. [PubMed] [Google Scholar]
  24. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., Trimarchi C., Paoletti E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995 Apr;13(6):539–549. doi: 10.1016/0264-410x(94)00028-l. [DOI] [PubMed] [Google Scholar]
  25. Taylor J., Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine. 1988 Dec;6(6):466–468. doi: 10.1016/0264-410x(88)90091-6. [DOI] [PubMed] [Google Scholar]
  26. Taylor J., Tartaglia J., Rivière M., Duret C., Languet B., Chappuis G., Paoletti E. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand. 1994;82:131–135. [PubMed] [Google Scholar]
  27. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine. 1991 Mar;9(3):190–193. doi: 10.1016/0264-410x(91)90152-v. [DOI] [PubMed] [Google Scholar]
  28. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988 Dec;6(6):497–503. doi: 10.1016/0264-410x(88)90100-4. [DOI] [PubMed] [Google Scholar]
  29. Taylor J., Weinberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Appel M., Norton E., Paoletti E. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology. 1992 Mar;187(1):321–328. doi: 10.1016/0042-6822(92)90321-f. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES